Mitomycin C in large infrequent doses in breast cancer

Wise, Gregory R.; Kuhn, Irvin N.; Godfrey, Thomas

doi:10.1002/mpo.2950020106

Cited by 19 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMC as a single agent achieves 30% of global re sponse [7][8][9][10][11] in patients not previously treated and 24.3% in previously treated cases [12], This indicates that the activity of this drug is similar to that of other agents used in advanced breast cancer. VBL has a 20% response rate when administered as intermittent bolus injections [13].…”

Section: Discussionmentioning

confidence: 95%

Mitomycin-C and Vinblastine in Advanced Breast Cancer

Navarro

Bellmunt²,

Balañá³

et al. 1989

Oncology

View full text Add to dashboard Cite

Forty-two patients with metastatic breast cancer refractory to first-line therapies were treated with combination chemotherapy with mitomycin-C and vinblastine. A response to treatment was observed in 11 of 34 evaluable patients (32.3%), with 3 complete remissions (8.8%) and 8 partial remissions (23.5%). The median duration of response was 185+ days. The 12-month survival was 78% for responders, 48% for patients with stable disease and 0% for patients with progressive disease. The toxicity was acceptable with 20 episodes of moderate myelosuppression (58.8%) and 2 cases with congestive heart failure that responded to medical treatment. The MMC-VBL combination is an active regime for advanced breast cancer previously treated with antracyclines. This combination may be regarded as a standard second-line treatment for this type of tumor.

show abstract

Section: Discussionmentioning

confidence: 95%

Mitomycin-C and Vinblastine in Advanced Breast Cancer

Navarro

Bellmunt²,

Balañá³

et al. 1989

Oncology

View full text Add to dashboard Cite

show abstract

“…Despite this reduction, hematologic toxicity re mained dose-limiting, and the weekly schedule yielded no advantages over the previously described daily schedule. Although response rates as high as 67% have been report ed [6], large reviews [2,7.8] of pooled data from multiple studies have placed the response rate to intermittently administered single-agent mitomycin in patients with metastatic breast cancer at between 26 and 38% (table 1) [6,[9][10][11][12][13][14][15]. Not surprisingly, for patients exposed to mul tiple prior chemotherapy regimens, the response rate has been lower, ranging from 15 to 25% [11,12,15].…”

Section: Single-agent Trialsmentioning

confidence: 99%

Mitomycin: Its Evolving Role in the Treatment of Breast Cancer

Hortobágyi¹

1993

Oncology

View full text Add to dashboard Cite

Investigators have compiled extensive experience with mitomycin in the treatment of patients with breast cancer. Given as a single agent in intermittent schedules, mitomycin has induced responses of 26–38% in previously untreated patients and of 15–25% in those exposed to multiple prior chemotherapy regimens. Duration of response has been short. Toxicity, primarily myelo-suppression, is largely dose-dependent. The dose-dependent efficacy of mitomycin has not yet been addressed. Preclinical studies suggest that optimal single-agent results are obtained when mitomycin is given in intermittent, high-dose schedules. Combination chemotherapy with mitomycin has proven more effective than single-agent therapy. Mitomycin given in combination with doxorubicin produces higher response rates than have been obtained with mitomycin alone. The 3M combination (mitomycin/mitoxantrone/methotrexate) appears effective and well tolerated at the doses described. Future research should focus on the development of polychemotherapeutic regimens that can be delivered in sequential or alternating schedules. Such regimens may yield quicker responses, and thus improve survival, in patients with breast cancer.

show abstract

“…MMC, an antitumor antibiotic with alkylating activity, has demonstrated promising activity in MBC as a single agent, achieving objective response rates (ORRs) of approximately 35% and 25% in patients with chemo-naive and pretreated MBC, respectively [20][21][22][23]. MMC has also shown good efficacy in combination strategies for MBC; in a randomized phase III study in first-line MBC, epirubicin and MMC (EM) (± lonidamid) demonstrated at least equivalent efficacy, in terms of ORR, time to progression (TTP), OS, and tolerability compared with standard 5-FU/epirubicin/cyclophosphamide (FEC) [24].…”

mentioning

confidence: 99%

Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer

Vrdoljak

Boban²,

Omrčen³

et al. 2011

neo

View full text Add to dashboard Cite

Optimal first-line chemotherapy for metastatic breast cancer (MBC) is challenging, particularly in patients previously treated with (neo) adjuvant anthracyclines/taxanes. Based on preclinical synergy with mitomycin C (MMC) and capecitabine in human tumor xenografts, we conducted a phase II study of first-line capecitabine and MMC in MBC. Patients received 3-weekly chemotherapy comprising MMC 8 mg/m 2 day 1 and capecitabine 1000 mg/m 2 twice daily, days 1-14. Combination chemotherapy was administered for a maximum six cycles, single-agent capecitabine could be continued until progressive disease or unacceptable toxicity. Thirty patients were included, objective response rate was 65.5%. After a median follow-up of 18.5 months, median time to progression was 8.5 months and median overall survival was 29.8 months. The main adverse events were thrombocytopenia, pneumonitis and hemolytic uremic syndrome. Our data suggest that first-line capecitabine and MMC has good antitumor activity in MBC, but is associated with MMC-specific toxicity.

show abstract

Mitomycin C in large infrequent doses in breast cancer

Cited by 19 publications

References 15 publications

Mitomycin-C and Vinblastine in Advanced Breast Cancer

Mitomycin-C and Vinblastine in Advanced Breast Cancer

Mitomycin: Its Evolving Role in the Treatment of Breast Cancer

Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer

Contact Info

Product

Resources

About